Gene therapy for ocular disorders
US11827898B2 · kind B2 · utility
0Cited by
23References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 2018 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Mar 17, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14171
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.